Anti-GAD antibody cerebellar ataxia mimicking Creutzfeldt-Jakob disease

Clinical Neurology and Neurosurgery

Volumn 109, Issue 1, 2007, Pages 54-57

  Chang, Chiung Chih ^a   Eggers, Scott D ^b   Johnson, Julene K ^a   Haman, Aissa ^a   Miller, Bruce L ^a   Geschwind, Michael D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b MAYO CLINIC   (United States)

Author keywords

14 3 3; Anti GAD65; Cerebellar ataxia; CJD; Glutamic acid decarboxylase antibody

Indexed keywords

CYCLOPHOSPHAMIDE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; IMMUNOGLOBULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; PROTEIN 14 3 3;

ADULT; ANAMNESIS; ARTICLE; ATAXIA; CASE REPORT; CEREBELLAR ATAXIA; CLINICAL FEATURE; CREUTZFELDT JAKOB DISEASE; DIFFERENTIAL DIAGNOSIS; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DYSARTHRIA; DYSMETRIA; FEMALE; HUMAN; HUMAN TISSUE; LABORATORY TEST; NEUROLOGIC EXAMINATION; PROTEIN CEREBROSPINAL FLUID LEVEL; REPEATED DRUG DOSE; UNSPECIFIED SIDE EFFECT;

14-3-3 PROTEINS; ANTIBODIES; CEREBELLAR ATAXIA; CREUTZFELDT-JAKOB SYNDROME; DIAGNOSIS, DIFFERENTIAL; FEMALE; GLUTAMATE DECARBOXYLASE; HUMANS; MIDDLE AGED;

EID: 33845187554     PISSN: 03038467     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clineuro.2006.01.009     Document Type: Article

References (27)

1. Lemstra A.W., et al. 14-3-3 testing in diagnosing Creutzfeldt-Jakob disease. Neurology 55 (2000) 514-516
2. Zerr I., et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt-Jakob disease. Neurology 55 6 (2000) 811-815
3. Hsich G., et al. The 14-3-3 brain protein in cerebrospinal fluid as a marker for transmissible spongiform encephalopathies. N Engl J Med 335 13 (1996) 924-930
4. Burkhard P., et al. CSF detection of the 14-3-3 protein in unselected patients with dementia. Neurology 56 (2001) 1528-1533
5. Geschwind M.D., et al. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt-Jakob disease. Arch Neurol 60 6 (2003) 813-816
6. Chapman T., McKeel Jr. D.W., and Morris J.C. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt-Jakob disease. Neurology 55 9 (2000)
7. de Seze J., et al. 14-3-3 Protein in the cerebrospinal fluid of patients with acute transverse myelitis and multiple sclerosis. J Neurol 249 5 (2002) 626-627
8. Hernandez Echebarria L.E., et al. Detection of 14-3-3 protein in the CSF of a patient with Hashimoto's encephalopathy. Neurology 54 7 (2000) 1539-1540
9. Martinez-Yelamos A., et al. 14-3-3 protein in the CSF as prognostic marker in early multiple sclerosis. Neurology 57 (2001) 722-724
10. Saiz A., et al. Detection of 14-3-3 brain protein in the cerebrospinal fluid of patients with paraneoplastic neurological disorders. Ann Neurol 46 (1999) 774-777
11. Satoh J., et al. The 14-3-3 protein detectable in the cerebrospinal fluid of patients with Prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture. Eur Neurol 41 (1999) 216-225
12. Rabinovici G.D., et al. First symptom in sporadic Creutzfeldt-Jakob disease. Neurology 66 2 (2006) 286-287
13. Dalakas M.C., et al. The clinical spectrum of anti-GAD antibody-positive patients with stiff-person syndrome. Neurology 55 10 (2000) 1531-1535
14. Honnorat J., et al. Cerebellar ataxia with anti-glutamic acid decarboxylase antibodies: study of 14 patients. Arch Neurol 58 2 (2001) 225-230
15. Nemni R., et al. Autoantibodies to glutamic acid decarboxylase in palatal myoclonus and epilepsy. Ann Neurol 36 4 (1994) 665-667
16. Vianello M., et al. Tremor of the mouth floor and anti-glutamic acid decarboxylase autoantibodies. Eur J Neurol 10 5 (2003) 513-514
17. Barova H., et al. Anti-GAD-positive patients with type 1 diabetes mellitus have higher prevalence of autoimmune thyroiditis than anti-GAD-negative patients with type 1 and type 2 diabetes mellitus. Physiol Res 53 3 (2004) 279-286
18. Aksamit A.J. Cerebrospinal fluid 14-3-3 protein: variability of sporadic Creutzfeldt-Jakob disease, laboratory standards, and quantitation. Arch Neurol 60 6 (2003) 803-804
19. WHO. Global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies: report of a WHO consultation. World Health Organization: emerging and other communicable diseases, surveillance and control. Geneva; 1998.
20. Shiga Y., et al. Diffusion-weighted MRI abnormalities as an early diagnostic marker for Creutzfeldt-Jakob disease. Neurology I63 (2004) 443-449
21. Young G.S., et al. Diffusion-weighted and fluid-attenuated inversion recovery imaging in Creutzfeldt-Jakob disease: high sensitivity and specificity for diagnosis. AJNR Am J Neuroradiol 26 6 (2005) 1551-1562
22. Ishida K., et al. Selective suppression of cerebellar GABAergic transmission by an autoantibody to glutamic acid decarboxylase. Ann Neurol 46 2 (1999) 263-267
23. Dalakas M.C., et al. Stiff person syndrome: quantification, specificity, and intrathecal synthesis of GAD65 antibodies. Neurology 57 5 (2001) 780-784
24. Rakocevic G., Raju R., and Dalakas M.C. Anti-glutamic acid decarboxylase antibodies in the serum and cerebrospinal fluid of patients with stiff-person syndrome: correlation with clinical severity. Arch Neurol 61 6 (2004) 902-904
25. Simsek-Duran F., Linden D.J., and Lonart G. Adapter protein 14-3-3 is required for a presynaptic form of LTP in the cerebellum. Nat Neurosci 7 12 (2004) 1296-1298
26. Aksamit Jr. A.J., Preissner C.M., and Homburger H.A. Quantitation of 14-3-3 and neuron-specific enolase proteins in CSF in Creutzfeldt-Jakob disease. Neurology 57 4 (2001) 728-730
27. Dalmau J., et al. Ma1, a novel neuron- and testis-specific protein, is recognized by the serum of patients with paraneoplastic neurological disorders. Brain 122 Pt 1 (1999) 27-39